NasdaqGS - Nasdaq Real Time Price USD

Lyell Immunopharma, Inc. (LYEL)

8.22

-0.51

(-5.89%)

At close: June 2 at 4:00:00 PM EDT

Lyell Immunopharma: Q1 Earnings Snapshot

SOUTH SAN FRANCISCO, Calif. AP) — Lyell Immunopharma Inc. LYEL) on Tuesday reported a loss of $52.2 million in its first quarter.

Associated Press Finance 20 days ago

LYEL
-5.89%
Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2025

Presenting new clinical data from Phase 1/2 multi-center clinical trial of LYL314, a next-generation dual‑targeting CD19/CD20 CAR T-cell product candidate for the treatment of relapsed and/or refractory large B‑cell lymphoma at the 18th International Conference on Malignant Lymphoma.Received Regenerative Medicine Advanced Therapy (RMAT) designation from the United States Food and Drug Administration (FDA) for LYL314 for the treatment of relapsed and/or refractory diffuse large B-cell lymphoma in

GlobeNewswire 20 days ago

LYEL
-5.89%
Lyell Immunopharma Announces Oral Presentation of New Clinical Data from the Phase 1/2 Trial of LYL314 for the Treatment of Large B-cell Lymphoma at the International Conference on Malignant Lymphoma (ICML) 2025

SOUTH SAN FRANCISCO, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage company advancing a pipeline of next-generation CAR T-cell therapies for patients with cancer, today announced that an abstract highlighting new clinical data from the Phase 1/2 trial of LYL314 (formerly IMPT-314) in large B-cell lymphoma will be presented as an oral presentation at the International Conference on Malignant Lymphoma (ICML) 2025 taking place in Lugano, Switzerla

GlobeNewswire last month

LYEL
-5.89%
$Lyell Immunopharma Receives Regenerative Medicine Advanced Therapy (RMAT) Designation for LYL314 for the Treatment of Relapsed and/or Refractory Large B-Cell Lymphoma$

Lyell Immunopharma Receives Regenerative Medicine Advanced Therapy (RMAT) Designation for LYL314 for the Treatment of Relapsed and/or Refractory Large B-Cell Lymphoma

RMAT designation was granted based on promising clinical data from the ongoing Phase 1/2 trial of LYL314 in patients with relapsed and/or refractory large B-cell lymphoma.RMAT designation recognizes the potential of LYL314 to address significant unmet needs of patients with relapsed and/or refractory large B-cell lymphoma and enables an increased frequency of communications with FDA on the development of LYL314Additional clinical data to be presented this year from the Phase 1/2 trial, including

GlobeNewswire last month

LYEL
-5.89%
Is Lyell Immunopharma, Inc. (LYEL) the Cheapest Stock Insiders Are Buying In March?

We recently published a list of 15 Cheapest Stocks Insiders Are Buying In March. In this article, we are going to take a look at where Lyell Immunopharma, Inc. (NASDAQ:LYEL) stands against other cheapest stocks insiders are buying in March. After solid gains Monday, the broader market index and blue chip companies traded flat Tuesday, […]

Insider Monkey 2 months ago

LYEL
-5.89%
Favourable Signals For Lyell Immunopharma: Numerous Insiders Acquired Stock

When a single insider purchases stock, it is typically not a major deal. However, when multiple insiders purchase...

Simply Wall St. 2 months ago

LYEL
-5.89%
Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2024

Acquired ImmPACT Bio and strengthened clinical pipeline with the addition of IMPT-314, a next-generation dual-targeting CD19/CD20 CAR T-cell product candidate for the treatment of aggressive large B-cell lymphoma (LBCL)Presented positive initial data from Phase 1 multi-center clinical trial of IMPT-314 in patients with aggressive LBCL in the 3rd line and later setting at the American Society of Hematology 2024 Annual MeetingAcceleration of development of IMPT-314 in LBCL; remain on track to init

GlobeNewswire 2 months ago

LYEL
-5.89%
Lyell Immunopharma Announces Participation in Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage company advancing a pipeline of next-generation CAR T-cell therapies for patients with cancer, today announced today that members of its senior management team will present and participate the following upcoming investor conferences: H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference on February 25th at 2:30 pm Eastern TimeTD Cowen's 45th Annual Health Care Conference

GlobeNewswire 3 months ago

LYEL
-5.89%
Lyell Immunopharma, Inc. (NASDAQ:LYEL) has caught the attention of institutional investors who hold a sizeable 46% stake

Key Insights Given the large stake in the stock by institutions, Lyell Immunopharma's stock price might be vulnerable...

Simply Wall St. 3 months ago

LYEL
-5.89%
Lyell Immunopharma (LYEL) Upgraded to Strong Buy: Here's Why

Lyell Immunopharma (LYEL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Zacks 4 months ago

LYEL
-5.89%
Lyell to Highlight Vision for its Next-Generation CAR T-Cell Therapy Pipeline at 43rd Annual JP Morgan Healthcare Conference

Accelerating IMPT-314 in large B-cell lymphoma; remain on track to initiate pivotal trial in the 3rd line+ setting in 2025 and expect to initiate a pivotal trial in the 2nd line by early 2026Presenting additional data from the ongoing Phase 1-2 trial in 3rd line+ setting and initial clinical data in 2nd line setting in mid-2025Discontinuing development of LYL119, a ROR1-targeting CAR T-cell product candidate for solid tumors, to focus resources on acceleration of pivotal trials of IMPT-314 and n

GlobeNewswire 4 months ago

LYEL
-5.89%
After Plunging -37.9% in 4 Weeks, Here's Why the Trend Might Reverse for Lyell Immunopharma (LYEL)

Lyell Immunopharma (LYEL) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Zacks 4 months ago

LYEL
-5.89%
After Plunging -31.22% in 4 Weeks, Here's Why the Trend Might Reverse for Lyell Immunopharma (LYEL)

Lyell Immunopharma (LYEL) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Zacks 4 months ago

LYEL
-5.89%
Down -30.89% in 4 Weeks, Here's Why Lyell Immunopharma (LYEL) Looks Ripe for a Turnaround

Lyell Immunopharma (LYEL) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Zacks 5 months ago

LYEL
-5.89%
Lyell Presents Positive Initial Clinical Data from the Phase 1-2 Clinical Trial of IMPT-314 for the Treatment of B-cell Lymphoma at the 2024 ASH Annual Meeting

Objective response rate (ORR) of 94% and a complete response (CR) rate of 71% demonstrated after IMPT-314 treatment in CAR T-naïve patients with large B-cell lymphoma who had received at least 2 prior lines of therapyManageable safety profile with no high-grade cytokine release syndrome (CRS) and low rates of Grade 3 immune effector cell-associated neurotoxicity syndrome (ICANS); adverse events were resolved with standard treatment protocolsInitial clinical data are consistent with clinical expe

GlobeNewswire 5 months ago

LYEL
-5.89%
Lyell Immunopharma (LYEL) Upgraded to Buy: Here's What You Should Know

Lyell Immunopharma (LYEL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks 6 months ago

LYEL
-5.89%
Lyell Immunopharma: Q3 Earnings Snapshot

SOUTH SAN FRANCISCO, Calif. AP) — Lyell Immunopharma Inc. LYEL) on Thursday reported a loss of $44.6 million in its third quarter.

Associated Press Finance 6 months ago

LYEL
-5.89%
Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2024

Acquired ImmPACT Bio and strengthened clinical pipeline with the addition of IMPT-314, a dual-targeting CD19/CD20 CAR T-cell product candidate with strong Phase 1 clinical data in patients with aggressive relapsed/refractory B-cell non-Hodgkin’s lymphomaPresenting initial data from Phase 1 multi-center clinical trial of IMPT-314 at the American Society of Hematology 2024 (ASH) Annual MeetingPresenting three abstracts at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting highlight

GlobeNewswire 6 months ago

LYEL
-5.89%
Lyell Announces Presentation of Initial Clinical Data from the Phase 1-2 Clinical Trial of IMPT-314 for the treatment of B-cell Lymphoma at the 2024 American Society of Hematology (ASH) Annual Meeting

SOUTH SAN FRANCISCO, Calif., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage company advancing a pipeline of next-generation CAR T-cell therapies for patients with solid tumors or hematologic malignancies, today announced that an abstract highlighting initial clinical data from the Phase 1-2 study of IMPT-314 in large B-cell lymphoma will be presented by Sarah M. Larson, M.D., Associate Professor, Department of Medicine, Medical Director, Immune Effect

GlobeNewswire 6 months ago

LYEL
-5.89%
LiveOne Leads The Pack Of 3 US Penny Stocks

As the U.S. stock market navigates a landscape shaped by tech earnings and labor market data, investors are keenly observing how these factors influence broader economic conditions. Penny stocks, despite being an older term, continue to capture attention for their potential to offer growth opportunities at lower price points. When these smaller or newer companies exhibit strong financial health and promising fundamentals, they can present compelling opportunities for investors seeking value...

Simply Wall St. 6 months ago

LYEL
-5.89%

LVO

CMRX

Performance Overview

Return	LYEL	S&P 500 (^GSPC)
YTD	-35.78%	+0.92%
1-Year	-85.16%	+12.48%
3-Year	-91.08%	+42.12%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Lyell Immunopharma, Inc. (LYEL)

Lyell Immunopharma: Q1 Earnings Snapshot

Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2025

Lyell Immunopharma Announces Oral Presentation of New Clinical Data from the Phase 1/2 Trial of LYL314 for the Treatment of Large B-cell Lymphoma at the International Conference on Malignant Lymphoma (ICML) 2025

Lyell Immunopharma Receives Regenerative Medicine Advanced Therapy (RMAT) Designation for LYL314 for the Treatment of Relapsed and/or Refractory Large B-Cell Lymphoma

Is Lyell Immunopharma, Inc. (LYEL) the Cheapest Stock Insiders Are Buying In March?

Favourable Signals For Lyell Immunopharma: Numerous Insiders Acquired Stock

Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2024

Lyell Immunopharma Announces Participation in Upcoming Investor Conferences

Lyell Immunopharma, Inc. (NASDAQ:LYEL) has caught the attention of institutional investors who hold a sizeable 46% stake

Lyell Immunopharma (LYEL) Upgraded to Strong Buy: Here's Why

Lyell to Highlight Vision for its Next-Generation CAR T-Cell Therapy Pipeline at 43rd Annual JP Morgan Healthcare Conference

After Plunging -37.9% in 4 Weeks, Here's Why the Trend Might Reverse for Lyell Immunopharma (LYEL)

After Plunging -31.22% in 4 Weeks, Here's Why the Trend Might Reverse for Lyell Immunopharma (LYEL)

Down -30.89% in 4 Weeks, Here's Why Lyell Immunopharma (LYEL) Looks Ripe for a Turnaround

Lyell Presents Positive Initial Clinical Data from the Phase 1-2 Clinical Trial of IMPT-314 for the Treatment of B-cell Lymphoma at the 2024 ASH Annual Meeting

Lyell Immunopharma (LYEL) Upgraded to Buy: Here's What You Should Know

Lyell Immunopharma: Q3 Earnings Snapshot

Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2024

Lyell Announces Presentation of Initial Clinical Data from the Phase 1-2 Clinical Trial of IMPT-314 for the treatment of B-cell Lymphoma at the 2024 American Society of Hematology (ASH) Annual Meeting

LiveOne Leads The Pack Of 3 US Penny Stocks

Performance Overview